SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-127611
Filing Date
2024-05-01
Accepted
2024-05-01 17:06:56
Documents
14
Period of Report
2024-05-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d779751d8k.htm   iXBRL 8-K 27262
2 EX-1.1 d779751dex11.htm EX-1.1 9933
  Complete submission text file 0001193125-24-127611.txt   163078

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA crvs-20240501.xsd EX-101.SCH 2864
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE crvs-20240501_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE crvs-20240501_pre.xml EX-101.PRE 11270
17 EXTRACTED XBRL INSTANCE DOCUMENT d779751d8k_htm.xml XML 3642
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 24903979
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)